
NICE recommends digital tech for ADHD diagnosis in children and young people
Betsy Goodfellow | July 16, 2024 | News story | Medical Communications | ADHD, Diagnostics, NICE
The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory committee has recommended the QbTest alongside standard clinical assessment to aid in the diagnosis of ADHD in children and young people between the ages of six and 17.
The newly recommended QbTest is a computer-based test which tracks a participant’s movements, while measuring three symptoms of ADHD: inattention, impulsivity and hyperactivity.
Results from the AQUA clinical trial demonstrated that using the QbTest along with a standard clinical assessment for ADHD led to a diagnostic decision being made for a greater proportion of people within six months of their first assessment appointment, compared to assessment not using the QbTest. The test was also able to rule out ADHD in more cases.
Mark Chapman, director of NICE’s HealthTech, commented: “Children and young people with ADHD deserve to receive a diagnosis in a timely manner. We heard from our patient experts there are challenges with current pathways. We’re committed to ensuring we get the best care to people fast while providing value for money to the taxpayer. This technology has the potential to generate tangible benefits to the lives of those waiting for an ADHD diagnosis. Evidence presented to our committee showed the QbTest could increase the number of children and young people who get a diagnostic decision within 6 months of starting assessment.”
Betsy Goodfellow
Related Content

InnotiveDx gets £1m grant to advance UTI diagnostics system
InnotiveDx has announced that it has received a £1m grant from Pathways to Antimicrobial Clinical …

University of Birmingham scientists develop new MRI contrast agent
Researchers at the University of Birmingham, UK, have developed a new class of magnetic resonance …

Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …





